Italian wealthy families seed startups, while fintech businesses keep raising funds.
Finscience, an Italian big data startup operating in the field of financial analysis, is launching a second capital increase after having raised one million of euros last NovemberĀ (see here aĀ previous post byĀ BeBeez).Ā Fabrizio Milano DāAragona, the companyās ceo,Ā Mauro Arte,Ā Claudio Zamboni, andĀ Alessandro Arrigo, the firmās general manager, founded Finscience.Ā The company raised its first round fundraising from Ā seasoned finance professional such asĀ Giuseppe Galimberti, a former banker ofĀ JP Morgan, Morgan Stanley, Deutsche Bank,Ā andĀ UBS;Ā Ugo Pastori, managing partner ofĀ WeisstorĀ and former ceo of hedge fundĀ Thalia. The list of investors also includesĀ Massimo Prelz Oltramonti, a former managing director ofĀ Advent International;Marco BelmondoĀ andĀ Guido Ferrarini, two of the owners ofĀ Epic sim;Ā Nicola CollaĀ andĀ Fabio NalucciĀ co-founders ofĀ Gellify.
Exor, the listed financial holding of theĀ AgnelliĀ Family, and its portfolio companyĀ PartnerReĀ invested in 11 US tech startups 20 million of US dollars throughĀ Exor SeedsĀ a venture firm with left resources worth 100 million (see here aĀ previous post byBeBeez).Ā Noam OhamaĀ heads Exor Seeds, an investor with a longer investment perspective than traditional venture capital firms.
BrunoĀ Farmaceutici, an Italian producer for anti dyabete drugs, investedĀ 75k euros inĀ InSilico Trials, an Italian SMEs which has developed a web platform for clinical trials that adopts simulations and algorithms instead of experiments with patients that is raising equity through the equity crowdfunding portalĀ CrowdFundMeĀ (see here aĀ previous Post byĀ BeBeez). Insilico Trials platform allows pharmaceutical companies to reduce by 50% R&D timing. The company is currently collaborating withĀ FDAĀ andĀ EMA, the US and EU drug agencies.Ā Insilico Trials raised 0.239 million overachievingĀ its 0.15 million target with a pre-money valuation of 9.4 million.
